
A leading provider of
innovative DNA Screening solutions
Rubinstein-Taybi Syndrome (RTS) is a well-defined condition characterized by short stature, mental retardation, facial abnormalities, and broad thumbs and first toes. It affects 1 in 100,000 newborns, and its phenotype has been associated with the disruption of a gene encoding a binding protein for cyclic adenosine monophosphate-response element binding protein (CBP) (CREBBP). Microdeletions including the CREBBP gene account for about 10-15% of RTS cases. Cytocell's Rubinstein-Taybi probe product covers 300 kb of the region encompassing the CREBBP gene so that larger deletions of the region can also be delineated.
Cat. No. LPU 023-S (5 tests)
Cat. No. LPU 023 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &